Evidence map›Paper›PMID 42469171›Full record

ArticleClinical pharmacology and therapeutics2026

Impact of Dolutegravir-, Lopinavir/Ritonavir-, and Efavirenz-Based Antiretrovirals on Piperaquine Pharmacokinetics in Ugandan Children Living with HIV.

Richard Kajubi, Malik Koire, Meghan E Whalen, Francis Orukan, Jaffer Okiring, Florence Marzan, Kacey Richards, Audun J Lier, Justin Goodwin, McKenzie Colt and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Richard KajubiInfectious Diseases Research Collaboration, Kampala, Uganda.
Malik KoireBaylor College of Medicine Children's Foundation Uganda, Kampala, Uganda.
Meghan E WhalenSchool of Pharmacy, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-7488-8976
Francis OrukanInfectious Diseases Research Collaboration, Kampala, Uganda.
Jaffer OkiringInfectious Diseases Research Collaboration, Kampala, Uganda.
Florence MarzanSchool of Pharmacy, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
Kacey RichardsSchool of Medicine, Yale University, New Haven, Connecticut, USA.
Audun J LierSchool of Medicine, Yale University, New Haven, Connecticut, USA.
Justin GoodwinSchool of Medicine, Yale University, New Haven, Connecticut, USA.
McKenzie ColtSchool of Public Health, Yale University, New Haven, Connecticut, USA.
Xay PhamSchool of Pharmacy, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
Sindy HeSchool of Pharmacy, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.ORCID https://orcid.org/0009-0002-2981-967X
Danny Hoi Tsun ChuSchool of Pharmacy, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.ORCID https://orcid.org/0009-0008-7011-1001
Bishop OpiraInfectious Diseases Research Collaboration, Kampala, Uganda.
Grace P KisituBaylor College of Medicine Children's Foundation Uganda, Kampala, Uganda.
Rogers SekabiraBaylor College of Medicine Children's Foundation Uganda, Kampala, Uganda.ORCID https://orcid.org/0009-0004-7902-9830
Adeodata KekitiinwaBaylor College of Medicine Children's Foundation Uganda, Kampala, Uganda.
Danh HuynhSchool of Pharmacy, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
Maggie KhourySchool of Pharmacy, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
Kathryn GallisonSchool of Pharmacy, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.ORCID https://orcid.org/0009-0007-3857-763X
Nikoletta FotakiDepartment of Life Sciences, University of Bath, Bath, UK.ORCID https://orcid.org/0000-0003-1826-7363
Moses W MwimaInfectious Diseases Research Collaboration, Kampala, Uganda.
Moses R KamyaInfectious Diseases Research Collaboration, Kampala, Uganda.ORCID https://orcid.org/0000-0001-9106-4234
Francesca T AweekaSchool of Pharmacy, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
Sunil ParikhSchool of Public Health, Yale University, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0001-9411-5180
Liusheng HuangSchool of Pharmacy, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-2702-4486
Norah MwebazaInfectious Diseases Research Collaboration, Kampala, Uganda.ORCID https://orcid.org/0000-0003-2195-0913

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dihydroartemisinin-piperaquine is increasingly used for malaria treatment and chemoprevention in children with HIV co-infection. Its efficacy and safety are associated with piperaquine exposure, which can be compromised by drug-drug interactions with antiretroviral therapy. In a prospective, open-label study, we evaluated the pharmacokinetics of piperaquine following a 3-day standard dihydroartemisinin-piperaquine regimen in malaria-uninfected Ugandan children living with HIV receiving either dolutegravir-, lopinavir/ritonavir-, or efavirenz-based antiretroviral therapies. Children without HIV aged 11-17 and 3-10 years were enrolled as control groups to match (a) the dolutegravir and (b) lopinavir/ritonavir and efavirenz groups, respectively (n = 30 per group). Intensive pharmacokinetic sampling for piperaquine over 42 days was completed. Compared to controls, overall piperaquine exposure, as measured by area under the concentration-time curve from the 3

Identifiers

PMID42469171
PMCPMC13379364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.